tbuckley/cabot-search huggingface dataset:
P47 The influence of muscle mass in the assessment of lower limb strength in copd
Authors: R Trethewey, D Esliger, E Petherick, R Evans, N Greening, B James, A Kingsnorth, M Morgan, M Orme, S Singh, L Sherar, N Toms, M Steiner
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Lower limb muscle strength measured by Quadriceps Maximal Voluntary Contraction (QMVC) provides valuable functional and prognostic information in people with COPD. Reference equations providing normal values for QMVC have been reported, some requiring measurement of muscle mass. It is unclear whether including muscle mass in the calculation significantly alters predicted values in COPD. We addressed this question by deriving reference equations for QMVC with and without the inclusion of whole body assessment of muscle mass in a cohort of healthy volunteers and subsequently comparing QMVC assessment using these reference equations in two separate cohorts of patients with COPD. <h3>Methods</h3> Prediction equations were derived through multiple linear regression in a healthy control (HC) group. Age, gender, height and weight were inputted into the first model (FFM– model) and fat-free mass (FFM) added for the other (FFM+ model). The prediction equations were then applied to a Primary Care COPD (PCC) group and Complex Care COPD (CCC) group of patients where percentage predicted values were calculated and weakness determined using a threshold of the lower limit of normal. <h3>Results</h3> 175 HC subjects (median (IQR) age: 54 (14) years, 31% male) were recruited. The PCC group comprised 87 patients (median (IQR) age: 68 (9) years, 71% male, FEV1 62 (20)% predicted) and the CCC group 189 patients (median (IQR) 66 (12) years, 57% male, FEV1: 29 (16)% predicted). Prediction values for the HC and PCC were similar between the FFM– and FFM+ models as shown in the table. In the CCC percentage predicted values were lower and there were 11.9% more classed as weak by the FFM– model compared to the FFM+ model. <h3>Conclusion</h3> The inclusion of fat-free mass did not significantly alter prediction of muscle weakness in the healthy cohort. In the COPD cohorts, including FFM in the model altered the proportion classified as having muscle weakness, most notably in the CCC cohort. This is likely to be due to a higher prevalence of muscle wasting in this population which resulted in an underestimate of predicted strength when muscle mass is included in the model.
P2.03b-011 Screening for ALK Abnormalities in Central Nervous System Metastases of Non-Small-Cell Lung Cancer
Authors: Marcin Nicoś, Bożena Jarosz, Pawel Krawczyk, Kamila Wojas-Krawczyk, Aleksandra Bożyk, Tomasz Kucharczyk, Marek Sawicki, Juliusz Pankowski, Tomasz Trojanowski, Janusz Milanowski
Journal: Journal of Thoracic Oncology (2017)
P1.02-017 Relative Abundance of EGFR Mutations Predict Tumor Metastasis and EGFR-TKIs Prognosis in Patients with Non-Small Cell Lung Cancer
Authors: Qiming Wang, Hongyan Wang, Hong Tang, Yufeng Wu, Zhen He, Lili Wang, Zhe Zhang, Dongdong Zhao, Li Yang, Bing Wei, Jie Ma, Yongjun Guo
Journal: Journal of Thoracic Oncology (2017)
Arhgap21+/- Mice Show Impaired Adhesion, Migration, Homing and Short Term Reconstitution of Hematopoietic Progenitor Cells
Authors: Juliana M. Xavier, Ricon Lauremília, Vieira Karla, Longhini Ana Leda, Franchi Gilberto, Nowill Alexandre, Carolina Bigarella, Sara T.O Saad
Journal: Blood (2014)
Sustained Phenotypic Correction of Murine Hemophilia A with Pre-Existing Anti-FVIII Immunity Using Lentivirus-Mediated Platelet-Specific FVIII Gene Transfer.
Authors: Qizhen Shi, Erin L. Kuether, Brian C. Cooley, Scot A. Fahs, Jocelyn A. Schroeder, David A. Wilcox, Robert R. Montgomery
Journal: Blood (2009)
Eosinophilic esophagitis versus proton pump inhibitor–responsive esophageal eosinophilia: Transcriptome analysis
Authors: Tetsuo Shoda, Akio Matsuda, Ichiro Nomura, Naoko Okada, Kanami Orihara, Hironobu Mikami, Norihisa Ishimura, Shunji Ishihara, Kenji Matsumoto, Yoshikazu Kinoshita
Journal: Journal of Allergy and Clinical Immunology (2017)
P3.02b-079 Effects of Icotinib with and without Radiation Therapy on Patients with EGFR Mutant Non-Small Cell Lung Cancer and Brain Metastases
Authors: Yun Fan, Yanjun Xu, Lei Gong, Lulu Miao, Hongyang Lu, Jing Qin, Na Han, Fajun Xie, Guoqing Qiu, Zhiyu Huang
Journal: Journal of Thoracic Oncology (2017)
Optimizing timelines of phase I dose finding studies through cohort size simulations
Authors: A. Miyamoto, R. Iacona
Journal: Journal of Clinical Oncology (2008)

6568 Background: A challenge of phase I studies is to select a dose for phase II in a timely manner, while ensuring patient's safety. There is also a desire to treat more patients at potentially efficacious doses. There are many obstacles to optimal study delivery: low starting dose; recruitment suspension while a cohort is in observation; need to replace non-evaluable (NE) patients; need to expand an initially small cohort to clarify safety signals. We have conducted simulation exercises quantifying: time for dose decision based on chance of a dose-limiting toxicity (DLT) and a patient being NE; the expected number of DLTs at a dose level. Methods: Consider a dose finding study design based on DLTs. Initially, 1 to 6 patients are enrolled at a dose level and observed for a pre-specified period of time. Depending on the number of DLTs, the next step is: (1 DLT) expand to 6 patients; (0 or 2 or more DLTs) explore another dose level or stop. In this presentation, we set observation period = 28 days; time to fill a new cohort = 1–7 days (random); time to replace a NE patient = 8–14 days (random). We explore initial cohort size = 1–6 patients, and a range of probabilities of DLT (P [DLT]) and of patient becoming NE (P [NE]). Results: Initial cohorts of sizes 1 or 6 result in faster and/or less variable time for dose level evaluation, compared to initial cohorts of 2–5 patients, irrespective of dose toxicity. Select results are shown in Table as median time (interquartile range [IQR]) (days) to complete a dose level. The expected number of DLTs at a dose level increases with 6 patient cohorts. Conclusions: If patients are likely to become NE or experience a DLT, enrolling the maximum cohort of 6 improves timelines, compared to enrolling 2–5 patients with intention to expand. An increase in DLTs with 6 patient cohorts, should be weighed against the decreased chance of escalating to an unacceptable dose level. At initial (very safe) dose levels, 1-patient cohorts offer substantial time advantage. Time needed to complete a dose level P(DLT) P(NE) Initial cohort size Time: median (IQR) 0.1 0.1 1 33 (31, 35) 0.1 0.1 3 35 (34, 61) 0.1 0.1 6 35 (34, 56) 0.1 0.2 1 33 (31, 36.5) 0.1 0.2 3 50 (34, 68) 0.1 0.2 6 53.5 (35, 67) 0.3 0.2 1 35 (31, 65) 0.3 0.2 3 53 (34, 68) 0.3 0.2 6 35 (35, 50) No significant financial relationships to disclose.
Detection of phosphoglucomutase-3 deficiency by lectin-based flow cytometry
Authors: Ryan J. Carlson, Michelle R. Bond, Shermaine Hutchins, Yishai Brown, Lynne A. Wolfe, Christina Lam, Celeste Nelson, Thomas DiMaggio, Nina Jones, Sergio D. Rosenzweig, Kelly D. Stone, Alexandra F. Freeman, Steven M. Holland, John A. Hanover, Joshua D. Milner, Jonathan J. Lyons
Journal: Journal of Allergy and Clinical Immunology (2017)
Donor Cell Leukemia: A Prospective Study of Its Identification and Treatment
Authors: Guillermo J Ruiz-Delgado, Monica P. Gonzalez-Ramirez, Nora A Martagon-Herrera, Javier Garces-Eisele, Alejandro Ruiz-Arguelles, Angelica Gonzalez-Cortes, Guillermo J. Ruiz-Arguelles
Journal: Blood (2014)
P175 Single centre experience of the real-life impact of pirfenidone on lung function in patients with idiopathic pulmonary fibrosis
Authors: A Rathnapala, A Fries, Y West, LP Ho, RK Hoyles
Journal: Thorax (2016)

<h3>Introduction</h3> Idiopathic pulmonary fibrosis (IPF) is a progressively destructive lung disease that culminates in respiratory failure and death. Trials have demonstrated that treatment of IPF patients with Pirfenidone reduces %FVC decline, improves progression-free survival and significantly reduces the risk of all-cause mortality at 1 year. Our anecdotal experience is that a small proportion of patients show improvement of %FVC with treatment. <h3>Objectives</h3> To assess the proportion of patients in an ILD specialist centre that improve, stabilise or decline in their %FVCs on Pirfenidone treatment. <h3>Methods</h3> In this retrospective study patients with IPF diagnosed according to the ATS/ERS guidelines at the ILD MDT, who were commenced and continued on Pirfenidone for &gt;6 months were included. Data was derived from the clinical records of the Oxford IPF clinic. <h3>Results</h3> 100 patient records were analysed and 31 were excluded (n = 15 &lt;6 months’ therapy, n = 5 inadequate data, n = 2 death &lt;1 month, n = 9 other). 58 (84.1%) male, 11 (15.9%) female; 38 (55.1%) had Definite IPF, 31 (44.9%) Probable IPF. Six months after commencing Pirfenidone (n = 69 patients), 5 (7.25%) experienced significant (&gt;10%) and 9 (13.04%) experienced marginal (5–10%) improvement in %FVC, 33 (47.83%) showed stability (−5% to 5% change %FVC), 10 (14.49%) showed marginal decline (−5% to −10%) and 12 (17.39%) showed significant (&gt;10%) decline in %FVC. After one year of Pirfenidone (n = 44 patients), 3 (6.8%) showed significant and 5 (11.4%) showed marginal improvement, 18 (40.9%) showed stability, 11 (25%) showed mild and 7 (15.9%) showed significant decline of %FVC. After 2 years of treatment (n = 15 patients), 1 (6.7%) showed significant and 3 (20%) showed mild improvement, 4 (26.7%) showed stability, 3 (20%) showed mild and 4 (26.7%) showed significant decline of the %FVC. Among 8 patients who had improvement in %FVC at one year, 6 were males, 6 had definite IPF, median age 77 years (68 – 84) and the median FVC was 73.5% predicted (66 – 79). <h3>Conclusions</h3> Real-life use of Pirfenidone shows clear slowing of decline in the %FVC, whereas a clinically significant subset show improvement in FVC. Potentially the beneficial effect is lost after 22–24 months, although small numbers limit this analysis.
P2.01-027 A Comparison of Five Different Immunohistochemistry Assays for Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer Samples
Authors: Ross Soo, Joey Lim, Bernadette Reyna Asuncion, Zul Fazreen, Maria Herrera, Feroz Omar, Ju Ee Seet, David Bryne, Shona Hendry, Stephen Fox, Richie Soong
Journal: Journal of Thoracic Oncology (2017)
Home Telemetric Monitoring of Pulmonary Function After Allogeneic Hematopoïetic Stem Cell Transplantation: Results of a Prospective Study Including 120 Patients.
Authors: Francois Lemonnier, Odile Randrianarivelo, Louis Jean Couderc, Marie Helene Becquemin, Nozha Bensalah, Madalina Uzunov, Elizabeth Rivaud, Stephanie Nguyen, Laurent Sutton, Jean Paul Vernant, Nathalie Dhedin
Journal: Blood (2009)
The Comparison of Platelet Parameters in Patients with Thrombocytopenia Associated with Acute Myeloid Leukemia and Immune Thrombocytopenia
Authors: Moon-Jin Kim, Jeong-Yeal Ahn, Pil-Whan Park, Yiel-Hea Seo, Kyung-Hee Kim, Ji-Hun Jeong, Mi-Jung Park, Jae-Hoon Lee, Jinny Park, Jun-Shik Hong
Journal: Blood (2012)
Role of GATA-1 and HSP70 in the Dyserythropoiesis of Early Myelodysplastic Syndromes.
Authors: Emilie Frisan, Julie Vandekerckhove, Cécile Pierre-Eugène, Aurélie de Thonel, Francois Dreyfus, Eric Solary, Catherine Lacombe, Patrick Mayeux, Carmen Garrido, Olivier Hermine, Michaela Fontenay
Journal: Blood (2009)
Association Between Early Lactate Levels and 30-Day Mortality in Clinically Suspected Sepsis in Children
Authors: Halden F. Scott, Lina Brou, Sara J. Deakyne, Allison Kempe, Diane L. Fairclough, Lalit Bajaj
Journal: JAMA Pediatrics (2017)

<h3>Importance</h3> Improving emergency care of pediatric sepsis is a public health priority, but optimal early diagnostic approaches are unclear. Measurement of lactate levels is associated with improved outcomes in adult septic shock, but pediatric guidelines do not endorse its use, in part because the association between early lactate levels and mortality is unknown in pediatric sepsis. <h3>Objective</h3> To determine whether the initial serum lactate level is associated with 30-day mortality in children with suspected sepsis. <h3>Design, Setting, and Participants</h3> This observational cohort study of a clinical registry of pediatric patients with suspected sepsis in the emergency department of a tertiary children's hospital from April 1, 2012, to December 31, 2015, tested the hypothesis that a serum lactate level of greater than 36 mg/dL is associated with increased mortality compared with a serum lactate level of 36 mg/dL or less. Consecutive patients with sepsis were identified and included in the registry following consensus guidelines for clinical recognition (infection and decreased mental status or perfusion). Among 2520 registry visits, 1221 were excluded for transfer from another medical center, no measurement of lactate levels, and patients younger than 61 days or 18 years or older, leaving 1299 visits available for analysis. Lactate testing is prepopulated in the institutional sepsis order set but may be canceled at clinical discretion. <h3>Exposures</h3> Venous lactate level of greater than 36 mg/dL on the first measurement within the first 8 hours after arrival. <h3>Main Outcomes and Measures</h3> Thirty-day in-hospital mortality was the primary outcome. Odds ratios were calculated using logistic regression to account for potential confounders. <h3>Results</h3> Of the 1299 patients included in the analysis (753 boys [58.0%] and 546 girls [42.0%]; mean [SD] age, 7.3 [5.3] years), 899 (69.2%) had chronic medical conditions and 367 (28.3%) had acute organ dysfunction. Thirty-day mortality occurred in 5 of 103 patients (4.8%) with lactate levels greater than 36 mg/dL and 20 of 1196 patients (1.7%) with lactate levels of 36 mg/dL or less. Initial lactate levels of greater than 36 mg/dL were significantly associated with 30-day mortality in unadjusted (odds ratio, 3.00; 95% CI, 1.10-8.17) and adjusted (odds ratio, 3.26; 95% CI, 1.16- 9.16) analyses. The sensitivity of lactate levels greater than 36 mg/dL for 30-day mortality was 20.0% (95% CI, 8.9%-39.1%), and specificity was 92.3% (90.7%-93.7%). <h3>Conclusions and Relevance</h3> In children treated for sepsis in the emergency department, lactate levels greater than 36 mg/dL were associated with mortality but had a low sensitivity. Measurement of lactate levels may have utility in early risk stratification of pediatric sepsis.
Common Variation at 6q25.3 (TULP4) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms
Authors: Roland Jäger, Ashot S Harutyunyan, Elisa Rumi, Bettina Gisslinger, Martin Schalling, Virginia Ferretti, Daniela Pietra, Mario Cazzola, Heinz Gisslinger, Robert Kralovics
Journal: Blood (2015)
S103 Non-typeable haemophilus influenzae downregulates release of beta-defensin-1 from bronchial epithelial cells
Authors: LJ Tregidgo, JL Cane, M Bafadhel
Journal: Thorax (2016)

<h3>Introduction</h3> Beta defensin-1 is an antimicrobial peptide released from epithelial cells, acting to defend the host against microbial activity and colonisation. It is possible that reduction in release of this antimicrobial peptide contributes to the host inability to remove bacteria from the airway. We investigated the release of beta-defensin-1 from the bronchial epithelium, with and without Non-Typeable<i> Haemophilus influenzae</i> (NTHi) infection and studied the effects of corticosteroids on this. <h3>Method</h3> Human bronchial epithelial cells from three healthy donors were grown to 90% confluence. Cells were treated with 16 nM, 1.6 nM and 0.16 nM Budesonide or 10 nM, 1 nM and 0.1 nM Fluticasone propionate as per clinical equivalence, for two hours prior to addition of 1 × 106 CFU of NTHi. Cells were incubated for a further two hours. Beta-defensin-1 was measured in supernatants by ELISA. <h3>Results</h3> NTHi infection downregulated beta-defensin-1 release by 42% (mean basal release: 133.6 pg/ml, SD: 61.6, mean release with NTHi infection: 77.6 pg/ml, SD: 50.6. p = 0.0084). Addition of Budesonide or Fluticasone propionate to bronchial epithelial cells decreased beta-defensin-1 release from mean basal level to 106.2 pg/ml (SD: 79.4, p = 0.023) and 100.6 pg/ml (SD: 50.0, p = 0.083) respectively. This release is synergistically decreased upon NTHi infection with Budesonide and Fluticasone propionate treatment (mean with NTHi: 67.3 pg/ml, SD: 38.7. p = 0.039 and 64.4 pg/ml, SD: 26.1. p = 0.048) respectively compared to corticosteroid treatment only. No difference in beta-defensin-1 level was seen between low and high dose of either corticosteroid tested. <h3>Conclusion</h3> NTHi inhibits beta-defensin-1 release from healthy bronchial epithelial cells. This release is dampened further by corticosteroid treatment and may be implicated in NTHi persistence in the airway in patients with chronic lung disease such as COPD.
P1.05-011 Comparative Analysis of TTF-1 Copy Number Alterations and Protein Expression in Patients with Non-Small Cell Lung Cancer
Authors: Katsuhiro Yoshimura, Yusuke Inoue, Nobuya Kurabe, Tomoaki Kahyo, Akikazu Kawase, Masayuki Tanahashi, Hiroshi Ogawa, Naoki Inui, Kazuhito Funai, Kazuya Shinmura, Hiroshi Niwa, Takafumi Suda, Haruhiko Sugimura
Journal: Journal of Thoracic Oncology (2017)
P1.07-038 Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas
Authors: Hao-Ran Zhai, Jia-Tao Zhang, Li-Xu Yan, Chao Zhang, Jian Su, Song Dong, Qiang Nie, Ri-Qiang Liao, Ben-Yuan Jiang, Xue-Ning Yang, Yi Long Wu, Wen-Zhao Zhong
Journal: Journal of Thoracic Oncology (2017)
Expression of HMGA2 in Blood Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria.
Authors: Yoshiko Murakami, Rieko Ohta, Norimitsu Inoue, Hideyoshi Noji, Tsutomu Shichishima, Jun-Ichi Nishimura, Yuzuru Kanakura, Taroh Kinoshita
Journal: Blood (2008)
The Cambridge Automated Neuropsychological Testing Automated Battery (CANTAB) Is Feasible and Valuable for the Evaluation of Neurocognitive Deficits in Pediatric Patients with Sickle Cell Disease: Results of a Pilot Study
Authors: Julie Kanter, Amber L Allison, Caitlin Henry, Sheryl Martin-Schild, Melody Benton, Ernest DeJean, Katarina Unger, Stacy Drury
Journal: Blood (2011)
P246 The in vitro effect of commonly used vasodilators on human pulmonary artery
Authors: A Hussain, R Bennett, K Kotidis, M Chaudhry, S Qadri, M Cowen, A Morice, M Loubani
Journal: Thorax (2016)

<h3>Introduction</h3> Acute pulmonary hypertension following cardiac surgery can have a significant effect on post-operative morbidity and mortality. The phosphodiesterase inhibitor sildenafil and the nitric oxide donor Sodium-Nitroprusside (SNP) are commonly used to treat pulmonary hypertension. The aim of this study was to characterise the pharmacological effects of clinically used vasodilators on the human pulmonary vasculature in comparison to the endogenous pulmonary vasodilators Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP). <h3>Methods</h3> Research ethics committee approval was obtained for the use of human tissue for this study. Patients undergoing lung resection were consented for their resected lung tissue to be included in the study. Patients under the age of 18 and who cannot give informed consent were excluded from the study and twelve patients were enrolled in this study. Pulmonary arteries were dissected from disease free areas of lung resection and 35 PA rings of internal diameter 2–4 mm and 2 mm long were prepared. PA rings were mounted in a multiwire myograph system containing Krebs-Henseleit solution (aerated with 21% O<sub>2</sub>: 5% CO<sub>2</sub> at 37<sup>o</sup>C) for measuring changes in isometric tension. A basal tension of 1.61 g was applied and the rings left to equilibrate for 60 min. After equilibration rings were pre-constricted to 11.21 µM PGF2α (EC<sub>80</sub>) then concentration response curves were constructed to Sildenafil, SNP, ANP and BNP by cumulative addition to the myograph chambers. The Integrity of the endothelium was confirmed with 1 μM Acetylcholine and smooth muscle viability was confirmed by exposure to potassium chloride. <h3>Results</h3> ANP was the most potent and effective vasodilator whereas BNP had little effect. SNP was marginally less potent and effective than ANP and the maximum effect of sildenafil was about 50% that of ANP. The EC<sub>50 </sub>for ANP, BNP, Sildenafil and SNP were 1.105 nM, 28.78 nM, 1.06 uM and 22.6 nM respectively. <h3>Conclusion</h3> This study demonstrated the differential effect of commonly used agonists on pulmonary vascular reactivity and this is the first comparison of these agents in human pulmonary arterial tissue. These effects may need to be considered in the clinical setting.
BRAF Mutations in Juvenile Myelomonocytic Leukemia.
Authors: Andrica C.H. de Vries, Ronald W. Stam, Christian Kratz, Martin Zenker, Oskar A. Haas, Elisabeth van Wering, Christian M. Zwaan, Franco Locatelli, Marco Zecca, Henrik Hasle, Jan Stary, Charlotte Marie Niemeyer, M.M. Van Den Heuvel
Journal: Blood (2007)
MA04.06 Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoresponse, Inflammation and DNA Repair
Authors: Sara Baglivo, Elisa Baldelli, Lucio Crinò, Vienna Ludovini, Rita Chiari, Giulio Metro, Chiara Bennati, Alex Hodge, Annamaria Siggillino, Francesca Romana Tofanetti, Ting Dong, Lorenza Pistola, Fortunato Bianconi, Angelo Sidoni, Vincenzo Minotti, Emanuel Petricoin, Mariaelena Pierobon
Journal: Journal of Thoracic Oncology (2017)
Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL
Authors: Viktoras Frismantas, Maria Pamela Dobay, Anna Rinaldi, Kunz Joachim, Blerim Marovca, Peter Horvath, Mauro Delorenzi, Gunnar Cario, Martin Schrappe, Martin Stanulla, Andreas E. Kulozik, Martina U. Muckenthaler, Arend Stackelberg, Cornelia Eckert, Thomas Radimerski, Beat Bornhauser, Jean-Pierre Bourquin
Journal: Blood (2015)
P2.03a-046 Safety and Efficacy Results From ABOUND.70+: nab-Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC
Authors: Corey Langer, Jonathan Goldman, Kathy Amiri, Eric Anderson, Shaker Dakhil, Daniel Haggstrom, Robert Jotte, Kartik Konduri, Manuel Modiano, Teng Ong, Alexandra Sanford, David Smith, Matei Socoteanu, Edward Kim, Jared Weiss
Journal: Journal of Thoracic Oncology (2017)
OA22.05 Breath Analysis by Gas Chromatography-Mass Spectrometry Can Be Used to Screen for Pleural Mesothelioma
Authors: Kevin Lamote, Lore Vandermeersch, Herman Van Langenhove, Joris Van Cleemput, Kristiaan Nackaerts, Jan Van Meerbeeck
Journal: Journal of Thoracic Oncology (2017)
PUB001 Advanced NSCLC Patients at the Extremes of Age in the Era of EGFR-TKIs
Authors: Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng Tseng, Wen-Feng Fang, Yu-Hsiu Chung, Yi-Hsi Wang, Mao-Chang Su, Kuo-Tung Huang, Chin-Chou Wang, Meng-Chih Lin
Journal: Journal of Thoracic Oncology (2017)
Enrichment and Expansion of Mart-1, NY-ESO and WT1 Specifc CD8+ T Cells Using Nano-Particle Artificial Antigen Presenting Cells (Nano-aAPCs)
Authors: Juan C. Varela, Karlo Perica, Christian Schuetz, Joan Bieler, Carl Haupt, Mathias Oelke, Jonathan Schneck
Journal: Blood (2014)